This company listing is no longer active
Fresh Tracks Therapeutics Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Bert Marchio
Chief executive officer
US$254.8k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 4.3yrs |
| CEO ownership | n/a |
| Management average tenure | 3.4yrs |
| Board average tenure | 3.2yrs |
Recent management updates
Recent updates
Brickell Biotech changes name to Fresh Tracks Therapeutics
Sep 07Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M
Aug 11Brickell Biotech regains Nasdaq compliance for minimum bid price requirement
Jul 20Here's Why Brickell Biotech (NASDAQ:BBI) Must Use Its Cash Wisely
Feb 14
Brickell Biotech's(NASDAQ:BBI) Share Price Is Down 16% Over The Past Year.
Jan 06
CEO
Bert Marchio (72 yo)
Mr. Albert Nicholas Marchio, II, also known as Bert, was Interim CFO & Principal Accounting Officer of NexImmune, Inc. from April 16, 2024 to August 27, 2024. He serves as Chief Financial Officer at Fresh...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, CFO | 4.3yrs | US$254.83k | no data | |
| VP of Finance & Chief Accounting Officer | 2.2yrs | no data | no data | |
| Head of Human Resource | 3.9yrs | no data | no data | |
| Interim Head of CMC Development | 2.9yrs | no data | no data |
Experienced Management: FRTX's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, CFO | 1.4yrs | US$254.83k | no data | |
| Member of Scientific Advisory Board | 3.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.2yrs | no data | no data |
Experienced Board: FRTX's board of directors are considered experienced (3.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/03 23:06 |
| End of Day Share Price | 2025/02/28 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fresh Tracks Therapeutics, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Thomas Flaten | Lake Street Capital Markets, LLC |
| Leland Gershell | Oppenheimer & Co. Inc. |